Aimin Zang

机构：Nanjing Drum Tower Hospital, Affiliated Hospital of Hebei University, Nanjing University · ORCID：0000-0001-6777-1959

发表论文 82 篇 · 总被引 2077 次 · h-index 21

代表论文

• Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01 (2024 · Journal of Clinical Oncology · 被引 163)
• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 89)
• ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer (2025 · Signal Transduction and Targeted Therapy · 被引 29)
• Cancer biomarkers discovered using pan-cancer plasma proteomic profiling (2025 · Nature Biomedical Engineering · 被引 10)
• First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors (2024 · npj Precision Oncology · 被引 9)
• Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study (2024 · The Lancet Respiratory Medicine · 被引 9)